EDU 13 - Integration of Radiotherapy with New Systemic Treatments for Breast Cancer
MODERATOR(S)
Naamit Gerber, MD - NYU Langone Medical Center
session DESCRIPTION
Advances in systemic therapies for breast cancer are reshaping clinical practice, introducing treatments with novel mechanisms of action and distinct side-effect profiles compared to traditional chemotherapy. However, clinical trials often focus on systemic therapies, offering limited guidance on their integration with radiotherapy. This knowledge gap complicates the safe and effective use of multimodal treatment approaches in curative and metastatic breast cancer settings. This session will provide an overview of integrating systemic therapies with radiotherapy, addressing evidence gaps and offering best-practice recommendations. Emphasis will be placed on patient-centered discussions about the risks, benefits and uncertainties of combined therapies to optimize outcomes. Dr. Torres will review data on adjuvant radiotherapy administered alongside systemic treatments, including CDK4/6 inhibitors for hormone receptor-positive breast cancer, anti-HER2 therapies such as TDM1 for HER2-positive cases, and capecitabine, PARP inhibitors, and immune therapies for TNBC. Dr. Meattini will explore the integration of radiotherapy with systemic treatments in metastatic breast cancer, where advances in systemic therapies have significantly extended survival. The session will examine the limited evidence on potential synergies and toxicities when combining these approaches. Dr. Beyer will address the complex management of CNS metastases in breast cancer patients, focusing on challenges posed by the blood-brain barrier and the biological diversity of breast cancer subtypes. The session emphasizes emerging strategies for combining systemic therapies with radiotherapy in this context. This session aims to equip attendees with actionable insights to enhance patient outcomes in this evolving landscape.
learning objectives
- Understand the potential toxicity of concurrent systemic agents and adjuvant breast radiation after seeing current data.
- Understand evidence regarding safety profile of new systemic therapies when used in combination or sequentially with ablative or palliative radiotherapy for metastatic breast cancer.
- Know the specific concerns regarding combined systemic therapy with radiation for treatment of CNS metastasis in breast cancer patients.
Credits
| AMA PRA Category 1 Credits: | 1.00 |
Presentations
-
08:00am - 09:00am PT
Integration of Radiotherapy with New Systemic Treatments for Breast Cancer
Speaker: Naamit Gerber, MD - NYU Langone Medical Center, Bronx -
08:00am - 08:02am PT
Introductions
Speaker: Naamit Gerber, MD - NYU Langone Medical Center, Bronx -
08:02am - 08:17am PT
Adjuvant Radiotherapy in Breast Cancer: Balancing Novel Systemic Therapies and Optimal Local Control
Speaker: Mylin Torres, MD, FASTRO - Emory University School of Medicine, Atlanta -
08:17am - 08:32am PT
Radiotherapy in the Metastatic Setting: Navigating Synergy, Sequencing, and Safety with Targeted Therapies
Speaker: Icro Meattini, MD - University of Florence, Florence -
08:32am - 08:47am PT
Central Nervous System Metastases in Breast Cancer: Challenges and Innovations in Systemic Therapy and Radiation Integration
Speaker: Sasha Beyer, MD, PhD - The Ohio State University, Columbus -
08:47am - 09:00am PT
Questions and Answers
Speaker: Naamit Gerber, MD - NYU Langone Medical Center, Bronx